866-997-4948(US-Canada Toll Free)

RG1678 Analysis and Forecasts from 2014 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 30 Pages


GlobalDatas pharmaceuticals report, RG1678 Analysis and Forecasts from 2014 to 2020 provides RG1678 sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Schizophrenia market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of RG1678 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of RG1678 including efficacy, safety, pricing and other details which influence its sales potential
  • Detailed sales forecast for 2014-2020 for RG1678 in each of the seven major markets
Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Schizophrenia 4
2.2 Symptoms 4
2.3 Schizophrenia Market 4
2.4 Epidemiology 4
2.5 Etiology 5
2.5.1 Genetic Factors 5
2.5.2 Environmental Factors 5
2.5.3 Abnormal Brain Structure 6
2.6 GlobalData Report Guidance 6

3 Schizophrenia: Market Characterization 7
3.1 Schizophrenia Market 7
3.2 Schizophrenia Market Forecasts and CAGR 7
3.3 Drivers of Schizophrenia Therapeutics Market 8
3.3.1 Patent Expiry of Leading Marketed Drugs 8
3.3.2 Increasing Patient Pool 8
3.3.3 High Prescription Rates 8
3.3.4 Low Patient Compliance Rate 8
3.3.5 High Unmet Need 8

4 Classification of Schizophrenia 9
4.1 Age of Onset of Schizophrenia 9
4.1.1 Pediatric / Adolescent / Childhood Schizophrenia 9
4.1.2 Adult Schizophrenia 10
4.2 Associated Symptoms 10
4.2.1 Paranoid Schizophrenia 10
4.2.2 Disorganized Schizophrenia 10
4.2.3 Catatonic Schizophrenia 10
4.2.4 Residual Schizophrenia 10
4.2.5 Undifferentiated Disorder 10

5 Treatment for Schizophrenia 11
5.1 Crisis Resolution Teams (CRT) 11
5.2 Voluntary and Compulsory Detention 11
5.3 Antipsychotics 11
5.3.1 Typical Antipsychotics 11
5.3.2 Atypical Antipsychotics 12
5.3.3 Increased Mortality in Elderly Patients with Dementia-Related Psychosis 12

6 RG1678 13
6.1 Introduction 13
6.2 Mechanism of Action 13
6.3 Clinical Studies 13
6.4 RG1678 Drug Development Status 14
6.5 Factors Affecting Sales of RG1678 14
6.5.1 First in Class Drug 14
6.5.2 High Unmet Need 14
6.5.3 PlaceboLike Safety Profile 14
6.6 Intensity of Competition 15
6.7 Sales Forecasts 15
6.7.1 Target Patient Pool of RG1678 15
6.7.2 Dosing 16
6.7.3 Market Penetration 16
6.7.4 Annual Cost of Therapy 17
6.7.5 Sales Projections of RG1678 17

7 Schizophrenia Market: Appendix 27
7.1 Market Definitions 27
7.2 Abbreviations 27
7.3 Research Methodology 27
7.4 Drug Sales Estimates Model 29
7.5 Contact Us 29
7.6 Disclaimer 30
7.7 Sources 30

List of Table


Table 1: RG1678, Drug Development Status, 2010 14
Table 2: RG1678, Comparison of Safety Profile with Placebo, Phase II Clinical Trials 15
Table 3: RG1678, Annual Treatment Costs, 2014 17
Table 4: RG1678, Schizophrenia, Global, Sales Forecasts ($m), 20142020 18
Table 5: RG1678, Schizophrenia, The US, Sales Forecasts ($m), 20142020 19
Table 6: RG1678, Schizophrenia, UK, Sales Forecasts ($m), 20142020 20
Table 7: RG1678, Schizophrenia, France, Sales Forecasts ($m), 20142020 21
Table 8: RG1678, Schizophrenia, Germany, Sales Forecasts ($m), 20142020 22
Table 9: RG1678, Schizophrenia, Italy, Sales Forecasts ($m), 20142020 23
Table 10: RG1678, Schizophrenia, Spain, Sales Forecasts ($m), 20142020 24
Table 11: RG1678, Schizophrenia, Japan, Sales Forecasts ($m), 20152020 25

List of Chart


Figure 1: Risk of Developing Schizophrenia 5
Figure 2: Environmental Factors in the Development of Schizophrenia 6
Figure 3: Schizophrenia, Global, Market Size Forecasts ($bn), 20102020 7
Figure 4: Classification of Schizophrenia based on the Age of Disease Onset 9
Figure 5: Drug Model Diagram of RG1678 16
Figure 6: RG1678, Schizophrenia, Global, Sales Forecasts ($m), 20142020 18
Figure 7: RG1678, Schizophrenia, The US, Sales Forecasts ($m), 20142020 19
Figure 8: RG1678, Schizophrenia, UK, Sales Forecasts ($m), 20142020 20
Figure 9: RG1678, Schizophrenia, France, Sales Forecasts ($m), 20142020 21
Figure 10: RG1678, Schizophrenia, Germany, Sales Forecasts ($m), 20142020 22
Figure 11: RG1678, Schizophrenia, Italy, Sales Forecasts ($m), 20142020 23
Figure 12: RG1678, Schizophrenia, Spain, Sales Forecasts ($m), 20142020 24
Figure 13: RG1678, Schizophrenia, Japan, Sales Forecasts ($m), 20152020 25
Figure 14: RG1678, Schizophrenia, Global, Sales Distribution in Major Countries (%), 2020 26

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *